Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease

Autor(es)

Borges, Cynthia M. ^[1] ; Fujihara, Clarice Kazue ^[2] ; Malheiros, Denise M. A. C. ^[3] ; de Avila, Victor Ferreira ^[2] ; Formigari, Guilherme Pedrom ^[1] ; Lopes de Faria, Jose B. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Fac Med Sci, Renal Pathophysiol Lab, Invest Diabet Complicat, Campinas, SP - Brazil

^[2] Univ Sao Paulo, Fac Med, Dept Clin Med, Renal Div, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Dept Pathol, Renal Pathol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY; v. 318, n. 5, p. F1229-F1236, MAY 2020.
• Citações Web of Science: 0

Resumo

Metformin. an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD). However, in all of these studies. the administration of metformin was initiated before the establishment of renal disease, which is a condition that does not typically occur in clinical settings. The aim of the present study was to investigate whether the administration of metformin could arrest the progression of established renal disease in a well-recognized model of CKD, the subtotal kidney nephrectomy (Nx) model. Adult male Munich-Wistar rats underwent either Nx or sham operations. After the surgery (30 days), Nx rats that had systolic blood pressures of >170 mmHg and albuminuria levels of >40 mg/24 h were randomized to a no-treatment condition or to a treatment condition with metformin (300 mg.kg(-1).day(-1)) for a period of either 60 or 120 days. After 60 days of treatment. we did not observe any differences in kidney disease parameters between Nx metformin-treated and untreated rats. However, after 120 days, Nx rats that had been treated with metformin displayed significant reductions in albuminuria levels and in markers of renal fibrosis. These effects were independent of any other effects on blood pressure or glycemia. In addition, treatment with metformin was also able to activate kidney AMPK and therefore improve mitochondrial biogenesis. It was concluded that metformin can arrest the progression of established kidney disease in the Nx model, likely via the activation of AMPK. (AU)

• Processo FAPESP: 14/22687-0 - Contribuição da via AMPK para a fibrose renal e patogênese da nefro e retinopatia diabéticas
• Beneficiário: Jose Butori Lopes de Faria
• Modalidade de apoio: Auxílio à Pesquisa - Temático